Dairy ingredients supplier Hoogwegt plans to purchase the first production material of cell-based whole milk from Canadian food technology company Opalia, marking a potential milestone in the development of alternative dairy ingredients. The material will be used for composition testing and product development, with fresh cheese, yogurt and butter among the potential applications.
The companies describe the planned transaction as a world first involving whole milk produced from bovine mammary cells. The initiative reflects growing interest in cellular agriculture as the dairy industry explores new production methods, alternative ingredient supplies and technologies that could complement conventional milk production.
However, the development remains at an early stage. Although Opalia has validated its production process at laboratory scale, the company still needs to demonstrate larger-scale production and obtain the necessary regulatory approvals before commercial food applications can advance.
Cell-Based Whole Milk Targets Traditional Dairy Applications
Montreal-based Opalia uses bovine mammary cells cultivated in a controlled bioreactor environment to produce milk containing proteins, fats and sugars. Unlike precision fermentation, which generally produces specific target proteins such as casein or whey proteins, Opalia’s approach aims to produce whole milk with a broader range of milk components.
This distinction could be significant for dairy product manufacturers. Whole milk contains multiple components that contribute to the texture, structure, flavour and processing characteristics of products such as cheese, yogurt and butter. Developing a cell-based milk suitable for these applications will require careful evaluation of its composition, functionality and performance under existing manufacturing conditions.
Opalia aims to supply milk and milk ingredients directly to food manufacturers while licensing its production technology to industry partners. According to the company’s stated approach, its cell-based milk could be processed into dairy products using established production methods, potentially reducing the need for entirely new downstream manufacturing systems.
Nevertheless, the suitability of the material for specific dairy applications will depend on testing and validation. The latest announcement does not provide detailed compositional data or results demonstrating finished-product performance.
Functional Performance Drives Alternative Dairy Ingredient Development
The planned collaboration comes as dairy ingredient suppliers and food manufacturers investigate different ways to improve functionality and diversify ingredient sources.
At IFT FIRST 2026, precision-fermentation company Standing Ovation showcased its Advanced Casein in gelato. The company reported that the ingredient supports texture and creaminess at an inclusion rate of 2–3%. This approach focuses on incorporating a particular dairy protein into a formulated product, whereas Opalia is pursuing the production of whole milk through cellular agriculture.
Both approaches illustrate how emerging technologies are targeting specific requirements within dairy processing. For manufacturers, the commercial value of alternative ingredients will depend not only on how they are produced but also on their ability to deliver consistent functionality, acceptable sensory characteristics and reliable performance at industrial scale.
Rising whey costs and tightening ingredient availability have also encouraged manufacturers to consider alternative protein supplies, ingredient blends and new production methods. Although cell-based whole milk differs from conventional dairy ingredients and precision-fermented proteins, it represents another technology being explored to address future ingredient needs.
Investment and Scale-Up Support Commercialisation Plans
Hoogwegt’s planned purchase builds on its existing investment in Opalia and a commercial agreement announced in August 2025. That agreement covered 2026 and 2027 and included a purchase order to support product development.
Opalia raised C$3.2 million, approximately US$2.28 million, in an initial seed funding close in April. The funding is intended to support the development of modular bioreactors and advance the company’s commercialisation plans.
Its planned production system targets an output of 28 litres of milk per day. While this capacity could support research, formulation work and early product development, substantially greater production capabilities would be needed to supply industrial-scale dairy ingredient markets.
The company plans to apply for regulatory approval in North America within the coming year and is targeting food-grade status in 2028. These milestones will be important in determining whether the technology can progress from laboratory development to broader commercial use.
Cellular agriculture is also attracting interest in conventional agricultural settings. In June, Dutch start-up RespectFarms inaugurated a cultivated meat pilot at a dairy farm in Schipluiden, the Netherlands. The project is exploring whether small-scale cell cultivation could create an additional revenue stream for farmers alongside traditional agricultural activities.
Fi Europe Presentation to Support Industry Partnerships
Opalia and Hoogwegt plan to present a prototype at Fi Europe in Frankfurt, Germany, from November 17–19, 2026. The companies intend to engage potential partners interested in supporting further development and exploring future commercial and offtake agreements.
The planned purchase represents an early step towards evaluating cell-based whole milk for dairy applications rather than evidence of an established commercial supply chain. The companies have not disclosed the purchase volume, transaction value or finished-product performance results.
For the dairy industry, the next phase will depend on successful scale-up, regulatory progress and evidence that cell-based milk can meet the technical and commercial requirements of food manufacturers. If these challenges can be addressed, the technology could become another option within a diversified dairy ingredient landscape, alongside conventional milk production and precision-fermented dairy proteins.